Bright Horizons Family Solutions enters the final stretch of Q3 with an unusual split: options traders have turned the least defensive in months, while the stock slides to its lowest level since early summer.
The standout this week is a dramatic shift in options positioning. The put/call ratio has collapsed from a 20-day average of 11.4 down to 3.98 — nearly three standard deviations below that mean, making it the most call-skewed reading in months. That's a sharp reversal from an extraordinarily hedged setup; a PCR above 10 had been the norm since late August, and the drop to sub-4 territory suggests either a significant unwinding of protective puts or fresh call buying. The 52-week range on the PCR runs from 0.02 to 28.7, so the current level is far from extreme on the call side — but the pace of the move is striking.
The short side tells a quieter story. At 4.4% of free float, short interest is down 3% on the week and has drifted lower for most of September after briefly touching nearly 3 million shares on September 15. Borrow conditions are among the loosest in the name's recent history: cost to borrow has fallen sharply to just 0.17%, more than 60% below where it stood a week ago, and borrow availability is exceptionally wide at nearly 8,000% — meaning roughly 80 shares remain available for every one already on loan. There is no pressure in the lending market. The ORTEX short score of 39.6 sits in the lower-middle of its range, consistent with the picture of a lightly shorted, easily borrowed name.
The Street is skeptical at the margin, and getting more so. Morgan Stanley's Toni Kaplan trimmed the Underweight target to $66 this week — just above the current price of $64.96 — signaling limited upside in the bear view. That $66 target now trails the stock by barely 1.5%. The consensus mean target of $89.22 implies substantial recovery potential, but the distribution behind that average is uneven: JP Morgan holds an Overweight with a $105 target, while Morgan Stanley's Underweight anchors the low end. Bulls are pointing to a forward EPS trajectory that the ORTEX factor scoring places in the 96th percentile for year-on-year estimate increases — a striking number for a name that has fallen roughly 11% over the past month to close at $64.96. Bears counter with the valuation: PE near 11.4x and EV/EBITDA at 8.7x are not distressed multiples for a services company with an uneven earnings record.
That earnings record is worth noting. The most recent print on July 30 sent the stock down nearly 10% on the day and 10.5% over the following five days — the kind of reaction that would explain the now-unwound put hedges that had been accumulating through August. The next earnings event is scheduled for November 2, giving the market roughly six weeks to reassess.
On the ownership side, BlackRock has become the dominant holder, filing a 13G in June showing a 12.5% stake — nearly triple its prior 4.3% disclosed position. Abrams Bison Investments filed a fresh 13G on September 17 at 5.6%, a new entrant at the threshold. No 13D activists are on the register. All 13D/G stakes are as last disclosed; holders dropping below 5% may not file again.
The November 2 print becomes the fulcrum: after a near-10% post-earnings drop in July, the question is whether the options reset — from extreme put-heavy to more balanced — reflects renewed confidence ahead of the next release, or simply the mechanical expiry of hedges that were never refreshed.
See the live data behind this article on ORTEX.
Open BFAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
